up-regulation of isocitrate dehydrogenase 1 is associated with non-small cell lung cancer.

High Plasma IDH1 levels were associated with non-small cell lung cancer.

Results demonstrated that wild-type IDH1 is over-expressed in lung adenocarcinoma which probably promoted tumor progression via increasing cancer stem cells survival.

Fibulin-5 silencing in non-small-cell lung cancer cells is due to the hypermethylation of its promoter through 2-hydroxyglutarate, production of which arises from a mutation in IDH1.

This study has identified an increased percentage of IDH1 and PCMTD1 mutations in Squamous Cell lung cancers arising in the Appalachian Kentucky residents versus The cancer Genome Atlas, with population-specific implications for the personalized treatment of this disease.

Translational value of IDH1 and DNA methylation biomarkers in diagnosing lung cancers: a novel diagnostic panel of stage and histology-specificity.

IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution.

Differential expression profiling of transcripts of IDH1, CEA, Cyfra21-1, and TPA in stage IIIa non-small cell lung cancer (NSCLC) of smokers and non-smokers cases with air quality index.